Lovastatin CAS: 75330-75-5
MF: C24H36O5
MW: 404.54
A hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels).

Lovastatin (CAS 75330-75-5)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 113ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Lovastatin is rated 3.0 out of 5 by 1.
5
0
4
0
3
1
2
0
1
0
Noms alternatifs: Mevacor;Monacolin K;mevinolin;6-α-Methylcompactin
Application: Lovastatin is a hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels)
Numéro CAS: 75330-75-5
Pureté: ≥97%
Masse Moléculaire: 404.54
Formule Moléculaire: C24H36O5
Pour la Recherche Uniquement. Non conforme pour le Diagnostic ou pour une Utilisation Thérapeutique.
* Consulter le Certificat d'Analyses pour les données spécifiques à un lot (incluant la teneur en eau).

Lovastatin is a statin natural product isolated from numerous sources including the Pleurotus ostreatus oyster mushroom, demonstrating hypocholesterolemic and antiproliferative properties. Lovastatin inhibits HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), blocking the enzyme-catalyzed transformation of 3-hydroxy-3-methylglutaryl CoA into mevalonate. The biosynthesis of cholesterol requires mevalonate as a building block and elimination of mevalonate generation subsequently interrupts cholesterol synthesis, leading to a reduction of circulating low-density lipoproteins. Lovastatin demonstrates arrest of the cell cycle at the G1 phase in bladder carcinoma T24 cells expressing activated p21ras oncoprotein - the posttranslational isoprenylation of the p21ras with mevalonate is crucial for translocation and membrane adhesion of the protein, and blockade of this modification by Lovastatin-induced depletion of cellular mevalonate leads to suspension of cell progress. The signaling activity of epidermal growth factor (EGF) and insulin-like growth factor (IGF-I) are similarly affected by impairment of mevalonate-dependent protein prenylation. Induction of apoptosis by Lovastatin in malignant mesothelioma cells is also ascribed to the inhibition of mevalonate synthesis and posttranslational protein modifications. Lovastatin is a substrate of CYP and Mdr-1.


Références

1. Alberts, A.W. 1988. Am. J. Cardiol. 62: 10J-15J. PMID: 3055919
2. Hancock, J.F., et al. 1989. Cell. 57: 1167-1177. PMID: 2661017
3. Mendola, C.E. and Backer, J.M. 1990. Cell Growth Differ. 1: 499-502. PMID: 2278880
4. Vincent, T.S., et al. 1991. Biochem. Biophys. Res. Commun. 180: 1284-1289. PMID: 1953779
5. Jakóbisiak, M., et al. 1991. Proc. Natl. Acad. Sci. U.S.A. 88: 3628-3632. PMID: 1673788
6. Rubins, J.B., et al. 1998. Am. J. Respir. Crit. Care Med. 157: 1616-1622. PMID: 9603146
7. Bobek, P., et al. 1998. Nutrition. 14: 282-286. PMID: 9583372
8. Kim, W.S., et al. 2001. Invest New Drugs. 19: 81-83. PMID: 11291836

État Physique :
Solid
Dérivé de :
Non-native source; synthetic
Solubilité :
Soluble in DMSO (10 mg/ml), ethanol (10 mg/ml), methanol, chloroform, acetone, acetonitrile, DMF, and water (0.4 µg/ml).
STOCKAGE :
Store at -20° C
Point de fusion :
175.4° C
Point d'Ébullition :
~559.2° C at 760 mmHg (Predicted)
Densité :
~1.1 g/cm3 (Predicted)
Indice de Réfraction :
n20D 1.53
Activité Optique :
α20/D 320°±10°, c = 0.5 in CH3CN
IC50 :
HMG-CoA reductase: IC50 = 0.01 µM (rat); Inhibition of the incorporation of sodium [14C]acetate into cholesterol: IC50 = 0.05 µM (HEP G2 cells); inhibition of recombinant ICAM-1 binding to purified immobilized LFA-1: IC50 = 3.78 µM; CYP51: IC50 = 200 µM (human)
Ki Data :
HMG-CoA reductase: Ki= 0.6 nM
Pour la Recherche Uniquement. Non conforme pour le Diagnostic ou pour une Utilisation Thérapeutique.
WGK Allemagne :
3
RTECS :
EK7907000
PubChem CID :
53232
Index Merck :
14: 5586
Numéro MDL :
MFCD00072164

Télécharger la Fiche de Sécurité/ SDS (MSDS)

CERTIFICAT D'ANALYSE

Pour une bonne lecture, Adobe Acrobat Reader est requis,
imprimer et commenter les documents PDF

Lovastatin (CAS 75330-75-5)  Références bibliographiques

Consultez les publications faisant référence à l' utilisation de Lovastatin (CAS 75330-75-5). Cliquez sur le lien pour afficher lentrée PubMed .

Citations 1 à 8 sur un total de 8

PMID: # 27159577  Shimada, K. et al. 2016. Nature chemical biology. 12: 497-503.

PMID: # 26243146  Meunier, S. et al. 2015. Nature communications. 6: 7889.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 9653194  De Petrocellis, L. et al. 1998. Proc. Natl. Acad. Sci. USA. 95: 8375-8380.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

PMID: # 32717915  Cells.

Citations 1 à 8 sur un total de 8
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 127ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 13ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

Santa Cruz Biotechnology, Inc. est leader mondial dans le développement de produits pour la recherche biomédicale. Contactez-nous au 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. Tous Droits Réservés. "Santa Cruz Biotechnology", et le logo Santa Cruz Biotechnology, Inc., "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", le logo San Juan Ranch, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", et "EZ Touch" sont des marques déposées de Santa Cruz Biotechnology, Inc.
Toutes les marques sont la propriété de leurs propriétaires respectifs.